$1.98
2.06% yesterday
NYSE, Sep 27, 10:00 pm CET
ISIN
US1420381089
Symbol
CRBU
Sector
Industry

Caribou Biosciences Stock price

$1.98
-0.18 8.33% 1M
-3.14 61.33% 6M
-3.75 65.45% YTD
-2.71 57.78% 1Y
-22.05 91.76% 3Y
-14.34 87.87% 5Y
-14.34 87.87% 10Y
NYSE, Closing price Fri, Sep 27 2024
+0.04 2.06%
ISIN
US1420381089
Symbol
CRBU
Sector
Industry

Key metrics

Market capitalization $175.30m
Enterprise Value $-59.02m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.45
EV/Sales (TTM) EV/Sales -1.78
P/S ratio (TTM) P/S ratio 5.29
P/B ratio (TTM) P/B ratio 0.56
Revenue growth (TTM) Revenue growth 132.34%
Revenue (TTM) Revenue $33.11m
EBIT (operating result TTM) EBIT $-141.58m
Free Cash Flow (TTM) Free Cash Flow $-130.95m
Cash position $261.65m
EPS (TTM) EPS $-1.39
P/E forward negative
P/S forward 14.17
EV/Sales forward negative
Short interest 13.20%
Show more

Is Caribou Biosciences a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,901 stocks worldwide.

Caribou Biosciences Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Caribou Biosciences forecast:

7x Buy
88%
1x Hold
13%

Analyst Opinions

8 Analysts have issued a Caribou Biosciences forecast:

Buy
88%
Hold
13%

Financial data from Caribou Biosciences

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
33 33
132% 132%
100%
- Direct Costs 5.65 5.65
34% 34%
17%
27 27
173% 173%
83%
- Selling and Administrative Expenses 34 34
18% 18%
104%
- Research and Development Expense 129 129
32% 32%
390%
-136 -136
16% 16%
-411%
- Depreciation and Amortization 5.65 5.65
34% 34%
17%
EBIT (Operating Income) EBIT -142 -142
17% 17%
-428%
Net Profit -123 -123
11% 11%
-373%

In millions USD.

Don't miss a Thing! We will send you all news about Caribou Biosciences directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Caribou Biosciences Stock News

Neutral
GlobeNewsWire
about one month ago
BERKELEY, Calif., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced company leadership will participate in the following event and investor conferences:
Neutral
GlobeNewsWire
about 2 months ago
-- Highly-experienced hematologist and oncologist with proven track record successfully driving global clinical development of CAR-T cell therapies -- BERKELEY, Calif., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the appointment of Tina Albertson, MD, PhD, as chief medical o...
Neutral
Accesswire
3 months ago
NEW YORK, NY / ACCESSWIRE / July 14, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Caribou Biosciences, Inc. ("Caribou" or the "Company") (NASDAQ: CRBU). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
More Caribou Biosciences News

Company Profile

Caribou Biosciences, Inc. engages in the development of an internal pipeline of off-the-shelf CAR-T and CAR-NK cell therapies. Its tools and technologies provide transformative capabilities to basic and applied biological research, therapeutic development, agricultural biotechnology, and industrial biotechnology. The company was founded by Jennifer A. Doudna, Rachel E. Haurwitz, Martin Jinek and James Berger on October 28, 2011 and is headquartered in Berkeley, CA.

Head office United States
CEO Rachel Haurwitz
Employees 158
Founded 2011
Website www.cariboubio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today